Support teaching, research, and patient care.
Dr. Andra Blomkalns is a national leader and an innovation advocate who promotes that the best patient-centered programs depend upon clinical practice innovation, continuous data-driven improvement, and interdisciplinary collaboration. Prior to Stanford, Dr. Blomkalns served as Division Chief of General Emergency Medicine and Vice Chair for Academic Affairs and Business Development at University of Texas Southwestern (UTSW) Department of Emergency Medicine. Reflecting her dual passions for patient care and innovation, she also served on the Intellectual Property Advisory Committee and was the clinical liaison to the Office for Technology Development. Prior to UTSW, Dr. Blomkalns served as Program Director and later Vice Chair of Education where she trained in Emergency Medicine at the University of Cincinnati. She earned her undergraduate degree from Rice University, medical degree from Louisiana State Health Sciences Center, and also holds and Master’s in Business Administration specializing in innovation and entrepreneurship from the University of Texas.
Dr. Andra Blomkalns is an innovation advocate who believes the best patient-centered programs depend upon clinical practice innovation, continuous data-driven improvement, and interdisciplinary collaboration. Dr. Blomkalns has a long-standing history of scholarship and publication on cardiovascular emergencies, point-of-care testing, innate immunity, and obesity. She has authored or contributed to more than 14 chapters and more than 40 journal articles in peer-reviewed publications on topics influential to administration and organization, clinical best practices, and scientific exploration. Additionally, her grant portfolio diversity reflects her multi-pronged, collaborative approach, and includes institutional, investigator-initiated industry, and federal funding.
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or
in combination, against the virus that causes COVID-19. Study drug(s) will be given to
participants with early symptoms of COVID-19. Samples will be taken from the back of the nose
to determine how much virus is in the body at various times during the study. Participation
could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the
remainder of assessments performed in the home, local clinic, or by phone.
View full details
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the
virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early
symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much
virus is in the body at various times during the study. Participation could last about 12
weeks and includes one required visit to the study site, with the remainder of assessments
performed in the home or by phone.
Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm
(Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113.
Enrollment began on August 19, 2022 and completed on February 21, 2023.
Stanford is currently not accepting patients for this trial.
For more information, please contact , 833-277-0197.